These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 8739811)

  • 1. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects.
    Dingemanse J; Jorga K; Zürcher G; Fotteler B; Sedek G; Nielsen T; van Brummelen P
    Eur J Clin Pharmacol; 1996; 50(1-2):47-55. PubMed ID: 8739811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
    Jorga KM; Sedek G; Fotteler B; Zürcher G; Nielsen T; Aitken JW
    Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.
    Dingemanse J; Jorga K; Zürcher G; Schmitt M; Sedek G; Da Prada M; Van Brummelen P
    Br J Clin Pharmacol; 1995 Sep; 40(3):253-62. PubMed ID: 8527287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans.
    Dingemanse J; Jorga KM; Schmitt M; Gieschke R; Fotteler B; Zürcher G; Da Prada M; van Brummelen P
    Clin Pharmacol Ther; 1995 May; 57(5):508-17. PubMed ID: 7768073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.
    Jorga K; Fotteler B; Schmitt M; Nielsen T; Zürcher G; Aitken J
    Eur Neurol; 1997; 38(1):59-67. PubMed ID: 9252801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers.
    Jorga KM
    Neurology; 1998 May; 50(5 Suppl 5):S31-8. PubMed ID: 9591520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy.
    Jorga KM; Fotteler B; Heizmann P; Zürcher G
    Eur J Clin Pharmacol; 1998 Jul; 54(5):443-7. PubMed ID: 9754991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.
    Baas H; Zehrden F; Selzer R; Kohnen R; Loetsch J; Harder S
    Clin Pharmacokinet; 2001; 40(5):383-93. PubMed ID: 11432539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COMT inhibition in the treatment of Parkinson's disease.
    Ruottinen HM; Rinne UK
    J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
    Gasser UE; Jorga K; Crevoisier C; Hovens SE; van Giersbergen PL
    Eur Neurol; 1999; 41(4):206-11. PubMed ID: 10343151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of COMT inhibition on levodopa pharmacology and therapy.
    Goetz CG
    Neurology; 1998 May; 50(5 Suppl 5):S26-30. PubMed ID: 9591519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
    Jorga KM; Nicholl DJ
    Br J Clin Pharmacol; 1999 Sep; 48(3):449-52. PubMed ID: 10510160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.
    Jorga K; Banken L; Fotteler B; Snell P; Steimer JL
    Clin Pharmacol Ther; 2000 Jun; 67(6):610-20. PubMed ID: 10872643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism.
    Jorga KM; Davis TL; Kurth MC; Saint-Hilaire MH; LeWitt PA; Fotteler B; Zürcher G; Rabbia M
    Clin Neuropharmacol; 2000; 23(2):98-105. PubMed ID: 10803800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
    Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
    J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial.
    Rajput AH; Martin W; Saint-Hilaire MH; Dorflinger E; Pedder S
    Neurology; 1998 May; 50(5 Suppl 5):S54-9. PubMed ID: 9591523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
    Limousin P; Pollak P; Pfefen JP; Tournier-Gervason CL; Dubuis R; Perret JE
    Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.